logo
Want to live to a healthy old age? Here's what a top doctor does based on hard science

Want to live to a healthy old age? Here's what a top doctor does based on hard science

CTV News7 days ago

Exercise is the most important thing a person can to do extend their health span, longevity researcher Dr. Eric Topol says. DjelicS/E+/Getty Images via CNN Newsource
Who among us wouldn't want to live a good life well into our 90s, especially if we could do it disease-free while still being as witty and spry as Betty White, as eloquent as Toni Morrison or as civically engaged as Jimmy Carter?
But you'd need good genes to live that long, right?
Not necessarily, according to Dr. Eric Topol, founding director of the Scripps Research Translational Institute in La Jolla, California, and former chairman of cardiovascular medicine at the Cleveland Clinic.
For almost 20 years, Topol has been studying a group of 1,400 Super Agers, or people who reached the age of 80 and beyond without developing one of three common, chronic, age-related conditions (cancer, heart disease and neurodegenerative disease), as part of the Wellderly study.
To his surprise, when his team conducted whole-genome sequencing on all the Wellderly study participants, the researchers found nothing genetic, across the board, that conferred an age and health advantage.
Topol's new book, 'Super Agers: An Evidence-Based Approach to Longevity,' explores the other factors at play and the science that backs them up. He examines lifestyle factors such as diet, exercise and sleep. He also looks at new technologies including the following :
polygenic risk scores that sift through a person's DNA to quantify disease risk;
the new science of 'omics' (for example, proteomics to analyze the complete set of proteins expressed by a body) that can be used to produce organ clocks measuring how fast our individual organs are aging; and
artificial intelligence to synthesize all available health data points.
All these technologies show promise in helping more people, if not reach Super Ager status, then achieve a longer health span by either delaying the onset of disease or aggressively treating conditions to prevent progression and complications.
Topol, who will soon turn 71, practices what he preaches.
'I hope to be (a Super Ager),' he told CNN Chief Medical Correspondent Dr. Sanjay Gupta, recently, on his podcast Chasing Life. 'If I can get another 10 or 15 years without an age-related disease, that'd be great. And I've really doubled down on the things that I can do to help get there.'
Exactly which steps has the doctor-scientist who studies Super Agers taken to increase his odds of reaching their ranks?
'I made extensive changes from the research, once we learned that it isn't in your genes … to achieve healthy aging, free of cancer, free of cardiovascular disease and free of neurodegenerative disease,' Topol said.
Lessons taken to heart: exercise, sleep and diet
One of the biggest changes Topol said he made was to his exercise routine. 'I used to only do aerobic exercise, and as a cardiologist, that was my thing,' he said. 'Now I do balance training and strength training (as well). It's an extensive difference. … And so, I'm more strong and fit than I've ever been.'
In fact, exercise is so important that Topol ranks it as No. 1 on the list for anyone who wants to get started on the path of a longer life.
'It's free. And if you're not doing anything, if you're a sedentary, then start with walks, brisk walks if you can, and keep increasing it,' he said. 'Challenge yourself (with) hills and pace … if you are working up a sweat, that's a really good sign.' (Check with your doctor before starting any new exercise routine.)
To get your upper body in shape, he recommends resistance bands, and to improve balance, he said to practice standing on one foot, then the other. 'These are all free or cost minimum,' he said, noting that with a few inexpensive items you can do your workout at home (like he does), no gym membership required. 'So work on that and then other things will start to fall in place. … If you exercise more, you'll sleep better, too.'
Which brings us to the next major change Topol made.
'I realized how important (sleep) is because of 'glymphatics.' That was a new insight in the book: about deep sleep and getting these waste products out of your brain,' he said, referring to the recently discovered glymphatic system, which helps flush out waste products in the brain and central nervous system, much like the lymphatic system does for the rest of the body.
'I was a poor sleeper,' he confessed, so he worked 'extensively' on improving the different factors that could impact it. 'Things like … what do I eat? And when do I eat? Also hydrating, mostly early in the day … to have less interrupted sleep.' He added that for him fasting is 'detrimental' to his sleep, as are both exercising or eating a big meal too late in the evening.
And, do not give short shrift to sleep regularity, Topol advised. 'I used to go to sleep all over the place (in terms of time), and now I'm very regimented, except for maybe one night a week,' he said, noting that this tweak was 'phenomenally effective' in levelling up his sleep game.
As for diet, Topol (who hasn't touched red meat in 40 years but does eat fish) said he wasn't surprised the evidence showed that a plant-based diet with enough lean protein 'prevailed as the best.'
'What was interesting, though, is how toxic (and) pro inflammatory ultraprocessed foods were,' he said, adding that he does everything he can to minimize UPF — which he jokingly calls UFOs, or alien food . 'It's hard to get it to zero, but I've (made a) conscious effort.'
Topol said he also increased his protein intake 'some,' due to his age and because he started strength training, 'but I don't go to toxic levels that are advocated by others, that have no evidence (and) that are pro-inflammatory.'
He said he keeps protein to about 90 grams a day for his 180-pound (82-kilogram) frame, by adding nuts, legumes (including beans) and more fish, even canned tuna in water, to his diet.
'I generally eat a salad every night,' he said. 'Now I'm a little more conscious about having something with it. … But (it's) not the protein craze that's being advocated by some of the extremists.'
Supplements, alcohol and stress
What about supplements and vitamins? 'I don't rule out that they could help (if) you have a specific deficiency — if for some reason your vitamin D is very low, or your vitamin B12,' Topol said.
But 'for healthy people who are not symptomatic (and) who take good care of themselves,' he said, 'there's no data to show that these provide any benefit' much less an antiaging one.
'I think they're a waste of money, and some of these supplements have potentially adverse effects,' he said. 'It's just infuriating because they're not regulated, so (marketers) can say anything, and people believe it and buy it.'
When it comes to consuming alcohol, Topol said he keeps his drinking 'light,' to fewer than seven drinks per week, after which the risks start adding up quickly. He said it doesn't seem to affect his own sleep, but it might impact that of others, so he recommends watching out for that.
Another top-of-the-list item: mental health and stress management. Topol mainly turns to exercise to help navigate both of these elements, but he said being out in nature is another often-overlooked route.
'The nature prescription is part of the book. There really is something to this,' he noted, adding that he takes advantage of San Diego's climate and location to do plenty of hiking and walking. 'It's good for mental health, it's good for stress and anxiety, just to be out in our environment.'
It's never too late to start any or all of these lifestyle adjustments, Topol said.
'These diseases take 20 years at least (to develop). So, you get even more (bang) if you start in your 40s and 50s or 60s … but if you start when you're 70 (or) 80, you're still going to derive years of healthy aging, maybe not quite as many, but still,' he said.
And because these common, chronic, age-related conditions — cancer, heart disease and neurodegenerative diseases — do take so long to fully manifest, Topol said we have time to intervene to change their trajectory.
Medical technologies gaining traction
But to fully leverage that latency period before the symptoms of a disease appear, it's important to be aware of personal risk, so people and their doctors (and society more broadly) can focus prevention and early detection efforts on the right people at the right time.
'Knowing one's risk — that's the next part, which is: we're going to prevent these three diseases in the future. We can now, and we're going to even get better at that,' Topol said.
Topol said he learned from his polygenic risk scores that he's at high risk for coronary artery disease, despite not having a family history. So, he has focused on getting his LDL cholesterol down. 'I've gotten it low, and perhaps I got more aggressive about that. I've checked my other lipids, like Lp(a) (lipoprotein[a]), so I feel like I've done everything I can to go into high prevent-mode for that.'
Topol said wants to get his immunome (all the genes and proteins of his immune system) mapped, to measure how well his immune system is functioning. It's a measurement he believes will one day soon be commonplace for everyone. He already has data on 'every virus I've ever been exposed to and every autoantibody that I have.'
He also plans on having his organ clocks measured, because different organs (such as the heart and brain) age at different rates, putting people at higher risk for certain diseases. 'I think it's going to be very helpful, because then I'll know (how) my heart organ clock correlates with my risk of heart disease.
'So those are some of the things I've done and/or I want to do,' he said.
'It's an extraordinary time in medicine, because we have a path to prevention,' Topol said, 'because of the way the science of aging (is developing), with these metrics like organ clocks and protein biomarkers and our genetics — all these layers of data — we are going to be able to prevent these diseases. And that's exciting. We've never done that before.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Canadian wildfire smoke causes 'very unhealthy' conditions in American Midwest and reaches Europe
Canadian wildfire smoke causes 'very unhealthy' conditions in American Midwest and reaches Europe

National Post

timean hour ago

  • National Post

Canadian wildfire smoke causes 'very unhealthy' conditions in American Midwest and reaches Europe

Article content Hennepin Healthcare, the main emergency hospital in Minneapolis, has seen a slight increase in visits by patients with respiratory symptoms aggravated by the dirty air. Article content Dr. Rachel Strykowski, a pulmonologist, said there is usually a bit of a delay before patients come in, which is unfortunate because the sooner those patients contact their doctors, the better the outcome. Typical symptoms, she said, include 'increase in shortness of breath, wheezing, maybe coughing a bit more, and flares of their underlying disease, and that's usually COPD and asthma.' Article content What happens, Strykowski said, is that the fine particulate matter from the wildfire smoke triggers more inflammation in patients' airways, aggravating their underlying medical conditions. Article content Strykowski noted that this is usually a time those patients can go outside and enjoy the summer weather because there are fewer triggers, so the current ones forcing them to stay inside can feel 'quite isolating.' Article content People can protect themselves by staying indoors or by wearing N95 masks, she said. Strykowski added that they must be N95s because the cloth masks many people used during the COVID-19 pandemic don't provide enough filtration. Article content Canada is having another bad wildfire season, and more than 27,000 people in three provinces have been forced to evacuate. Most of the smoke reaching the American Midwest has been coming from fires northwest of the provincial capital of Winnipeg in Manitoba. Article content Winnipeg hotels opened Monday to evacuees. More than 17,000 Manitoba residents have been displaced since last week, including 5,000 residents of the community of Flin Flon, nearly 400 miles (645 kilometers) northwest of Winnipeg. In neighboring Saskatchewan, 2,500 residents of the town of La Ronge were ordered to flee Monday, on top of more than 8,000 in the province who had been evacuated earlier. Article content Article content In Saskatoon, where the premiers of Canada's provinces and the country's prime minister met Monday, Saskatchewan Premier Scott Moe said all of Canada has come together to help the Prairie provinces. Article content Article content Two people were killed by a wildfire in mid-May in Lac du Bonnet, northeast of Winnipeg. Article content Canada's worst-ever wildfire season was in 2023. It choked much of North America with dangerous smoke for months. Article content The smoke reaches Europe Article content Canada's wildfires are so large and intense that the smoke is even reaching Europe, where it is causing hazy skies but isn't expected to affect surface-air quality, according the European climate service Copernicus. Article content The first high-altitude plume reached Greece and the eastern Mediterranean just over two weeks ago, with a much larger plume crossing the Atlantic within the past week and more expected in coming days, according to Copernicus. Article content 'That's really an indicator of how intense these fires are, that they can deliver smoke,' high enough that they can be carried so far on jet streams, said Mark Parrington, senior scientist at the service. Article content The fires also are putting out significant levels of carbon pollution — an estimated 56 megatonnes through Monday, second only to 2023, according to Copernicus. Article content

High Content Screening Market worth US$2.19 billion in 2030 with 7.5% CAGR
High Content Screening Market worth US$2.19 billion in 2030 with 7.5% CAGR

Globe and Mail

timean hour ago

  • Globe and Mail

High Content Screening Market worth US$2.19 billion in 2030 with 7.5% CAGR

"The prominent players operating in the high content screening market are Danaher Corporation (US), Revvity, Inc. (US), BD (US), Carl Zeiss AG (Germany), Merck KGaA (Germany), and Thermo Fisher Scientific, Inc. (US), among others." Browse 363 market data Tables and 31 Figures spread through 358 Pages and in-depth TOC on "High Content Screening Market by Product & Services (Instrument (Cell Imaging, Analysis System), Consumables (Reagents & Assay Kits, Microplates), Software), Application (Drug Discovery & Development, Toxicology), End User - Global Forecast to 2030 The global High Content Screening Market, valued at US$1.47 billion in 2024, is forecasted to grow at a robust CAGR of 7.5%, reaching US$1.52 billion in 2025 and an impressive US$2.19 billion by 2030. Al and machine learning advancements enhance image analysis capabilities, improving the accuracy and efficiency of high-throughput screening. The expanding applications of HCS in personalized medicine, oncology research, and cell- based assays contribute to market growth. Furthermore, government funding for cell-based research and the rising prevalence of chronic diseases are increasing the adoption of HCS technologies across various research fields. Key segments positively impacting the market include high-content imaging platforms, which dominate due to their critical role in drug discovery and cellular research. Among applications, drug discovery and development lead the market, with pharmaceutical and biotechnology companies being the largest end users due to their extensive R&D investments. The rising adoption of toxicology screening and target identification further supports market growth. Browse in-depth TOC on " High Content Screening Market" 363 - Tables 31 - Figures 358 - Pages By Based on cell detection and analysis system segment, the market is segmented by instrument into high content imaging platforms, cell detection and analysis systems, and cell imaging systems. The high content imaging platforms segment dominated the market in 2024. High content imaging platforms hold a significant share in the market owing to their critical role in cellular analysis, drug discovery, and phenotypic screening. These platforms enable high-throughput imaging of live and fixed cells, providing detailed cellular morphology and functional insights necessary for drug screening, toxicity assessment, and disease modelling. By Based on Primary and Secondary screening, the application segment is divided into drug discovery & development applications, toxicology, and basic research. The drug discovery & development application segment is further divided into primary screening and secondary screening, target identification and validation, compound profiling, and other drug discovery & development applications. The rising focus on precision medicine, personalized therapies, and high-throughput screening applications has reinforced the demand for high content imaging systems in research and clinical settings. By Based on end user, the market is segmented into pharmaceutical & biotechnology companies, academic & government institutes, and CROs & CDMOs. pharmaceutical & biotechnology companies dominated the segment in 2024 and is anticipated to grow at the highest CAGR during the forecast period of 2025-2030. Dominance of the segment is attributable to increasing complexity of drug candidates, particularly in oncology, immunology, and neurological disorders, which has further boosted the demand for HCS in cellular imaging and phenotypic screening. Moreover, the growing trend of precision medicine and biologics development also contributes to the increased utilization of HCS technologies, which is supporting the segment growth in high content screening market. By geography, the high content screening market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the market due to a strong presence of leading academic institutions and market players, substantial investments in biotechnology and pharmaceutical research, and advanced healthcare infrastructure. Asia-Pacific (APAC) is witnessing rapid growth, due to the rising prevalence of chronic diseases, increasing healthcare investments, and expanding research capabilities. Countries like China, India, and Japan are experiencing substantial advancements in biotechnology and drug discovery, supporting to the growing demand for high content screening technologies. Request Sample Pages: The prominent players operating in the high content screening market are Danaher Corporation (US), Revvity, Inc. (US), BD (US), Carl Zeiss AG (Germany), Merck KGaA (Germany), and Thermo Fisher Scientific, Inc. (US), among others. Danaher (US) is one of the leading players in the high content screening market. The company has a presence in more than 60 countries and offers a diversified product portfolio of instruments and software in the high content screening market. Danaher strongly focuses on organic and inorganic growth strategies to maintain a dominant position in the market. The company operates in the market through Beckman Coulter, Molecular Devices, and Integrated DNA Technologies, among others. Danaher's robust global distribution network and dedicated customer support help the company to maintain its dominant position in the market. Revvity, Inc. (US) is one of the dominant players in the high content screening market. The company has a global presence in more than 150 countries and has diversified products for the high content screening market. The company's product offerings include instruments, software, and consumables such as automated cell counter, flow cytometer, microscope, cell imaging systems, and microplate readers. A robust global distribution network and customer-centric approach ensure Revvity serves diverse sectors, including academia, biotechnology, and pharmaceuticals. For more information, Inquire Now!

Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer
Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer

Globe and Mail

time2 hours ago

  • Globe and Mail

Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer

BRADENTON, Fla. , June 4, 2025 /CNW/ -- Continuity Biosciences, LLC, a developer of advanced drug delivery technologies, announced today the acquisition of Focal Medical, Inc., a North Carolina -based biopharmaceutical company pioneering site-specific chemotherapy using iontophoresis. The acquisition represents a key step in Continuity's strategy to become a leader in device targeted therapeutics for intractable solid tumors. Founded by leading scientists and clinicians, Focal Medical has developed a proprietary platform that delivers chemotherapy directly to tumors using iontophoresis —this minimally-invasive technique utilizes a mild electrical current to drive therapeutic compounds into targeted tissues. This method enhances local drug concentration while minimizing systemic toxicity, a critical need in the treatment of pancreatic and other solid-tissue cancers. Focal Medical's lead product candidate, an iontophoresis device directed gemcitabine therapy for pancreatic cancer, has been cleared by the U.S. Food and Drug Administration (FDA) through an Investigational New Drug (IND) application. Phase 1b clinical trials are expected to begin later this year. "This is a transformative milestone for Continuity Biosciences," said Ramakrishna Venugopalan , PhD, MBA, Chief Executive Officer of Continuity Biosciences. "Focal Medical's approach to localized drug delivery aligns perfectly with our vision to improve bioavailability, reduce systemic exposure, and deliver better outcomes for patients. We are thrilled to bring this promising platform into our portfolio and into the clinic." Through the acquisition, Continuity Biosciences obtains Focal Medical's entire patent estate, iontophoresis technology platform and specialized equipment, scientific know-how, and licensing agreements with the University of North Carolina at Chapel Hill . In addition, key scientific staff and leadership from Focal will join Continuity, further enhancing its internal capabilities. A dedicated research and development facility in Cary, NC that supports ongoing platform and pipeline advancement is also part of the acquisition and will be expanded to support other delivery platforms. Visionary Founders Driving the Innovation Focal Medical was co-founded by: Jen Jen Yeh , MD , a surgical oncologist and professor at UNC-Chapel Hill with joint appointments in Surgery and Pharmacology. She serves as assistant dean of translational research in UNC School of Medicine and associate director of translational research in UNC Lineberger Comprehensive Cancer Center. Dr. Yeh is widely recognized for her expertise in pancreatic cancer and translational oncology. Joseph DeSimone , PhD , an award-winning chemist, entrepreneur, and academic, currently serving as the Sanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering at Stanford University . He is globally known for his breakthroughs in materials science, nanomedicine, and advanced manufacturing, including 3D printing. Their iontophoresis system is designed to deliver gemcitabine, an FDA-approved chemotherapy agent, directly into pancreatic tumors. Traditional systemic administration of gemcitabine is often limited by poor tumor penetration and significant toxicity. Focal's approach bypasses those limitations by delivering the drug directly to the tumor site with high precision and minimal systemic toxicity. "After nearly a decade of R&D, we are excited to join the Continuity Biosciences family," said Tony Voiers , Acting CEO of Focal Medical. "We are grateful to our founders, scientific collaborators, and investors who have helped us reach this pivotal point. Partnering with Continuity ensures that this novel therapy moves forward into the clinic where it has the potential to help patients facing one of the deadliest cancers." This acquisition reinforces Continuity Biosciences' commitment to building a diverse portfolio of clinically meaningful drug delivery platforms and signals a decisive move toward becoming a clinical-stage leader in site-specific therapy. About Continuity Biosciences Continuity Biosciences, LLC is a biopharmaceutical company developing advanced drug delivery technologies that address the limitations of conventional therapeutic administration. With operations in Bradenton, FL ; Houston, TXRaleigh, NC ; and Torino, Italy , the company focuses on combination drug-device platforms for chronic and complex conditions. Visit:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store